Akeso Inc. reported significant progress in 2024, including approvals for cadonilimab and ivonescimab in multiple cancer indications, successful inclusion in the National Reimbursement Drug List (NRDL), and expansion of its global clinical trials. The company achieved RMB 2 billion in new drug sales, representing a 25% year-on-year increase, and continues to advance its oncology and non-oncology pipelines.